文献速递流行病学与生物统计医学教育与科研方法

潜在冗余随机对照试验的患病率及相关因素:一项横断面研究

Prevalence of and factors associated with potentially redundant randomized controlled trials: a cross-sectional study.
PubMed 文献 · J Clin Epidemiol · 2024-01-22

该横断面研究基于2020至2021年发表的4500篇随机抽取的参考文献,纳入448项符合条件的荟萃分析,发现12.7%(95%CI 9.8-16.2%)的荟萃分析包含潜在冗余随机对照试验;在333项低异质性荟萃分析中该比例为17.1%(95%CI 13.5-21.5%)。57项荟萃分析中潜在冗余随机对照试验共295项(涉及85385名参与者),占这些荟萃分析纳入随机对照试验的38.5%(参与者的30.3%)。

要点

  • 12.7%的近期荟萃分析包含潜在冗余随机对照试验,低异质性亚组为17.1%。
  • 潜在冗余随机对照试验共295项,涉及85385名参与者,占相关荟萃分析随机对照试验的38.5%。
  • 评估药物干预、纳入超过5项随机对照试验或最早随机对照试验报告显著效应时更易出现冗余。

核心结论

  • 近期发表的荟萃分析中12.7%至17.1%包含潜在冗余随机对照试验,凸显开展或审查现有证据的系统评价以论证新随机对照试验的重要性。
  • 研究识别了冗余更可能发生的一些场景,对试验研究者、资助机构、伦理委员会和期刊编辑具有启示意义。

研究设计与样本

  • 横断面研究,基于2020至2021年发表、索引于PubMed、Embase或Cochrane系统评价数据库的4500篇随机抽取参考文献,通过系统评价和荟萃分析相关术语全面检索。
  • 从每篇系统评价中纳入一项符合以下全部条件的荟萃分析(若有):评估干预对系统评价主要结局的效果;仅合并随机对照试验。
  • 主要结局为包含潜在冗余随机对照试验的荟萃分析患病率;潜在冗余随机对照试验指在累积荟萃分析总体效应估计经试验序贯分析确定具有统计学稳健性后1年才开始的试验。
  • 记录每项合格荟萃分析中潜在冗余试验的数量(若有)及涉及参与者数,并进行组间比较;采用逻辑回归分析探讨潜在冗余存在的相关因素。

主要发现

  • 448项合格荟萃分析中,57项(12.7%,95%CI 9.8-16.2%)包含潜在冗余随机对照试验。
  • 限于333项低异质性荟萃分析,患病率为17.1%(95%CI 13.5-21.5%)。
  • 潜在冗余随机对照试验共295项(涉及85385名参与者),占57项荟萃分析纳入随机对照试验的38.5%(参与者的30.3%)。
  • 这些荟萃分析中,潜在冗余随机对照试验数中位数为2项(范围1-50),涉及参与者中位数为352名(范围17-26997)。
  • 评估药物干预(OR 2.31,95%CI 1.16-4.49)、评估疗效结局(OR 7.25,95%CI 0.85-61.87)、纳入超过5项随机对照试验(OR 6.47,95%CI 3.22-12.99)或最早随机对照试验报告统计学显著效应估计(OR 5.30,95%CI 2.64-10.64)的荟萃分析更可能存在潜在冗余随机对照试验。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the prevalence of meta-analyses containing potentially redundant randomized controlled trials (RCTs) and the factors associated with the presence of redundancy. STUDY DESIGN AND SETTING: This is a cross-sectional study, based on a random sample of references (n = 4500) that were published during 2020 and 2021, indexed in PubMed, Embase, or the Cochrane Database of Systematic Reviews, and retrieved through comprehensive searches using terms about systematic reviews and meta-analysis. From each systematic review, one meta-analysis fulfilling all the following criteria, if available, was included in this study: (1) assessing the effect of the intervention on a primary outcome of the systematic review; (2) combining RCTs only. The primary outcome was prevalence of meta-analyses containing potentially redundant RCTs. Potentially redundant RCTs referred to the trials that started 1 year after the overall effect estimate from cumulative meta-analysis had been statistically robust, as determined by trial sequential analysis when appropriate. The number of potentially redundant trials (if any) in each eligible meta-analysis and the number of participants involved in those trials were documented and contrasted across groups. Logistic regression analysis was conducted to explore the factors associated with presence of potential redundancy. RESULTS: Of the 448 eligible meta-analyses, 57 (12.7%, 95% confidence interval (CI) 9.8-16.2%) contained potentially redundant RCTs. When limited to the 333 low-heterogeneity meta-analyses, the prevalence was 17.1% (95% CI 13.5-21.5%). The total number of potentially redundant RCTs was 295 (involving 85,385 participants), accounting for 38.5% of the RCTs (and 30.3% of the participants) included in the 57 meta-analyses. In these meta-analyses, the median number of potentially redundant RCTs and the participants involved were 2 (range: 1-50) and 352 (range: 17-26997), respectively. Potentially redundant RCTs were more likely to be present in the meta-analyses evaluating pharmaceutical intervention (odds ratio [OR] 2.31, 95% CI 1.16-4.49), assessing efficacy outcomes (OR 7.25, 95% CI 0.85-61.87), containing more than 5 RCTs (OR 6.47, 95% CI 3.22-12.99), or with the earliest RCT reporting statistically significant effect estimate (OR 5.30, 95% CI 2.64-10.64). CONCLUSION: This study found that 12.7% to 17.1% of recently published meta-analyses contained potentially redundant RCTs, highlighting the importance of conducting or examining systematic reviews of existing evidence to justify new RCTs. More importantly, the study identified some scenarios in which redundancy was more likely to occur and thus has implications for trialists, funding agencies, ethics committees, and journal editors.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Yun Q, Lin M, Jia Y, et al. Prevalence of and factors associated with potentially redundant randomized controlled trials: a cross-sectional study. J Clin Epidemiol. 2024. PMID: 38266740. doi:10.1016/j.jclinepi.2024.111265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。